Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Oct;88(4):e13605.
doi: 10.1111/aji.13605. Epub 2022 Aug 2.

Efficacy of lymphocyte immunotherapy in the treatment of recurrent pregnancy loss from alloimmunity: A systematic review and meta-analysis

Phorenice D Francisco  1 , Carol Stephanie C Tan-Lim  2 , Maria Socorro L Agcaoili-De Jesus  1
Affiliations
Meta-Analysis

Efficacy of lymphocyte immunotherapy in the treatment of recurrent pregnancy loss from alloimmunity: A systematic review and meta-analysis

Phorenice D Francisco et al. Am J Reprod Immunol. 2022 Oct.

Abstract

Problem: The efficacy of lymphocyte immunotherapy (LIT) in the treatment of recurrent pregnancy loss (RPL) from alloimmunity has been debated for years. There is conflicting evidence on the therapeutic role of LIT, since the etiology of most cases of RPL is previously classified as idiopathic.

Method of study: A systematic search of PubMed and Cochrane databases was done for randomized controlled trials that assessed the efficacy of paternal lymphocyte or third donor LIT among patients with primary or secondary RPL. The primary outcome was live birth rate after LIT. Random-effect meta-analysis was conducted using the software RevMan 5.4. Pre-planned subgroup analyses of source of lymphocytes, timing and frequency of administration, and concentration per immunization dose were conducted.

Results: Data from eight trials showed a statistically significant benefit of LIT (RR = 1.45, 95% CI 1.05-2.01). The overall live birth rate is higher in the treatment group (65.6%) compared to placebo or no treatment (45.2%). Subgroup analysis based on source of lymphocytes revealed a trend towards benefit with paternal LIT but with wide confidence interval (RR = 1.34, 95% CI = .84-2.14). Multiple doses of immunotherapy before pregnancy and low dose (5×106 cells) LIT showed significant benefit. Sensitivity analysis involving studies with a low risk of bias demonstrated significant benefit of increased live birth rate among patients treated with LIT compared to those who received placebo or no treatment (RR = 1.97, 95% CI = 1.53-2.53).

Conclusion: LIT demonstrate benefit in improving pregnancy outcome of patients with RPL from alloimmunity.

Keywords: alloimmunity; lymphocyte immunotherapy; recurrent pregnancy loss.

PubMed Disclaimer

References

REFERENCES

    1. Bender Atik R, Christiansen O, Elson J, et al. ESHRE guideline: recurrent pregnancy loss. Human Reproduction Open. https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Recurrent-pregnancy... 2018 [cited 2020 September]
    1. Royal College of Obstetricians and Gynaecologists, Scientific Advisory Committee, Guideline No. 17. The Investigation and treatment of couples with recurrent miscarriage, 2011 [cited 2020 September]. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg17
    1. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2012;98(5):1103-1111.
    1. Pandey MK, Thakur S, Agrawal S, Lymphocyte immunotherapy and its probable mechanism in the maintenance of pregnancy in women with recurrent spontaneous abortion. Archives of Gynecol Obstet. 2004;269(3):161-172.
    1. Liu Z, Xu H, Kang X, et al. Allogenic lymphocyte immunotherapy for unexplained recurrent spontaneous abortion: a meta-analysis. Am J Reprod Immunol. 2016;76(6):443-453.

LinkOut - more resources